Single-center, Open-label, Non-randomized, Two-period Sequential Treatment Study to Assess the Effect of Neomycin on the Pharmacokinetics of Regorafenib in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2014
Price : $35 *
At a glance
- Drugs Regorafenib (Primary) ; Neomycin
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 31 Aug 2018 Biomarkers information updated
- 19 May 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.